PYRIMETHAMINE; SULFADOXINE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for pyrimethamine; sulfadoxine and what is the scope of freedom to operate?
Pyrimethamine; sulfadoxine
is the generic ingredient in one branded drug marketed by Roche and is included in one NDA. Additional information is available in the individual branded drug profile pages.Summary for PYRIMETHAMINE; SULFADOXINE
US Patents: | 0 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Clinical Trials: | 144 |
DailyMed Link: | PYRIMETHAMINE; SULFADOXINE at DailyMed |
Recent Clinical Trials for PYRIMETHAMINE; SULFADOXINE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Kamuzu University of Health Sciences | Phase 4 |
Malaria Consortium | Phase 3 |
Papua New Guinea Institute of Medical Research | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for PYRIMETHAMINE; SULFADOXINE
US Patents and Regulatory Information for PYRIMETHAMINE; SULFADOXINE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Roche | FANSIDAR | pyrimethamine; sulfadoxine | TABLET;ORAL | 018557-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |